BACKGROUND: Neuroimaging and electrophysiologic studies have consistently provided evidence of impairment in anterior cingulate cortex/medial frontal cortex function in people with schizophrenia. In this study, we sought to clarify the nature of this abnormality by combining proton magnetic resonance spectroscopy (1H-MRS) with functional magnetic resonance imaging (fMRI) at 3T. METHODS: We used single-voxel MRS acquired in the dorsal anterior cingulate cortex and fMRI during performance of a Stroop color-naming task to investigate the neurochemistry and functional response of the anterior cingulate cortex/medial frontal cortex in 26 stable, medicated subjects with schizophrenia and 23 matched healthy control subjects. RESULTS: In schizophrenia subjects, we found decreased blood oxygen level-dependent signal in the medial frontal wall, with significant clusters restricted to more dorsal regions compared with healthy subjects. In addition, we observed a trend-level decrease in N-acetylaspartate/creatine (NAA/Cr) levels and a significant positive correlation between NAA/Cr level and the blood oxygen level-dependent signal in schizophrenia subjects that did not exist in healthy subjects. Furthermore, in this group of medicated subjects, we did not find evidence of decreased glutamate + glutamine(Glx)/Cr levels, but there was a significant negative correlation between Glx/Cr levels and negative symptoms. CONCLUSIONS: Our results suggest that abnormal NAA levels, which may reflect a neuronal dysfunction related to schizophrenia, affect neuronal physiology, as evidenced by reduced blood oxygen level-dependent response.
BACKGROUND: Neuroimaging and electrophysiologic studies have consistently provided evidence of impairment in anterior cingulate cortex/medial frontal cortex function in people with schizophrenia. In this study, we sought to clarify the nature of this abnormality by combining proton magnetic resonance spectroscopy (1H-MRS) with functional magnetic resonance imaging (fMRI) at 3T. METHODS: We used single-voxel MRS acquired in the dorsal anterior cingulate cortex and fMRI during performance of a Stroop color-naming task to investigate the neurochemistry and functional response of the anterior cingulate cortex/medial frontal cortex in 26 stable, medicated subjects with schizophrenia and 23 matched healthy control subjects. RESULTS: In schizophrenia subjects, we found decreased blood oxygen level-dependent signal in the medial frontal wall, with significant clusters restricted to more dorsal regions compared with healthy subjects. In addition, we observed a trend-level decrease in N-acetylaspartate/creatine (NAA/Cr) levels and a significant positive correlation between NAA/Cr level and the blood oxygen level-dependent signal in schizophrenia subjects that did not exist in healthy subjects. Furthermore, in this group of medicated subjects, we did not find evidence of decreased glutamate + glutamine(Glx)/Cr levels, but there was a significant negative correlation between Glx/Cr levels and negative symptoms. CONCLUSIONS: Our results suggest that abnormal NAA levels, which may reflect a neuronal dysfunction related to schizophrenia, affect neuronal physiology, as evidenced by reduced blood oxygen level-dependent response.
Authors: Beth E Snitz; Angus MacDonald; Jonathan D Cohen; Raymond Y Cho; Theresa Becker; Cameron S Carter Journal: Am J Psychiatry Date: 2005-12 Impact factor: 18.112
Authors: Margaret R Lentz; John P Kim; Susan V Westmoreland; Jane B Greco; Robert A Fuller; Eva M Ratai; Julian He; Prabhat K Sehgal; Elkan F Halpern; Andrew A Lackner; Eliezer Masliah; R Gilberto González Journal: Radiology Date: 2005-03-29 Impact factor: 11.105
Authors: Mikael Landén; Pia Davidsson; Carl-Gerhard Gottfries; Jan-Eric Månsson; Kaj Blennow Journal: Schizophr Res Date: 2002-05-01 Impact factor: 4.939
Authors: Jean Théberge; Yousef Al-Semaan; Peter C Williamson; Ravi S Menon; Richard W J Neufeld; Nagalingam Rajakumar; Betsy Schaefer; Maria Densmore; Dick J Drost Journal: Am J Psychiatry Date: 2003-12 Impact factor: 18.112
Authors: Laura M Rowland; Elena A Spieker; Alan Francis; Peter B Barker; William T Carpenter; Robert W Buchanan Journal: Neuropsychopharmacology Date: 2008-12-03 Impact factor: 7.853
Authors: Eric Plitman; Shinichiro Nakajima; Camilo de la Fuente-Sandoval; Philip Gerretsen; M Mallar Chakravarty; Jane Kobylianskii; Jun Ku Chung; Fernando Caravaggio; Yusuke Iwata; Gary Remington; Ariel Graff-Guerrero Journal: Eur Neuropsychopharmacol Date: 2014-08-01 Impact factor: 4.600
Authors: Joshua Chiappelli; Laura M Rowland; S Andrea Wijtenburg; Florian Muellerklein; Malle Tagamets; Robert P McMahon; Frank Gaston; Peter Kochunov; L Elliot Hong Journal: Neuropsychopharmacology Date: 2015-02-27 Impact factor: 7.853
Authors: Thomas W Sedlak; Leslie G Nucifora; Minori Koga; Lindsay S Shaffer; Cecilia Higgs; Teppei Tanaka; Anna M Wang; Jennifer M Coughlin; Peter B Barker; Jed W Fahey; Akira Sawa Journal: Mol Neuropsychiatry Date: 2018-04-17
Authors: Nina Vanessa Kraguljac; Meredith Reid; David White; Rebecca Jones; Jan den Hollander; Deborah Lowman; Adrienne Carol Lahti Journal: Psychiatry Res Date: 2012-09-13 Impact factor: 3.222
Authors: Allison S Brandt; Paul G Unschuld; Subechhya Pradhan; Issel Anne L Lim; Gregory Churchill; Ashley D Harris; Jun Hua; Peter B Barker; Christopher A Ross; Peter C M van Zijl; Richard A E Edden; Russell L Margolis Journal: Schizophr Res Date: 2016-02-28 Impact factor: 4.939
Authors: Nina V Kraguljac; Meredith A Reid; David M White; Jan den Hollander; Adrienne C Lahti Journal: Neuropsychopharmacology Date: 2012-07-18 Impact factor: 7.853